Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q3 2019 Earnings Conference Call - Final Transcript
Nov 07, 2019 • 08:00 am ET
Welcome to the Lexicon Pharmaceuticals' Third Quarter 2019 Financial Results and Business Update. [Operator Instructions]
I will now turn the call over to Dr. Kimberly Lee, Head of Investor Relations and Corporate Strategy. Please go ahead Ms. Lee.
Thank you, Carmen [Phonetic]. Good morning and welcome to the Lexicon Pharmaceuticals third quarter 2019 financial results and business update conference call. Joining me on today's call are Lonnel Coats, Lexicon's President and Chief Executive Officer; Alex Santini, Executive Vice President and Chief Commercial Officer; Dr. Pablo Lapuerta, Executive Vice President and Chief Medical Officer, Dr. Praveen Tyle, Executive Vice President of Research and Development; and Jeff Wade, Executive Vice President of Corporate and Administrative Affairs and Chief Financial Officer. After our formal remarks, we will open the call up for Q&A.
Earlier today, Lexicon issued a press release announcing our financial results for the third quarter of 2019, which is available on our website at www.lexpharma.com and through our SEC filings. A webcast of this call along with a slide presentation will be accessible in our Investor Relations section of our website.
During this call, we will review the information provided in the release, provide an update on our clinical programs and then use the remainder of the time to answer your questions.
Before we begin, let me remind you that we will be making Forward-Looking Statements, including statements relating to the safety and efficacy and the therapeutic and commercial potential of XERMELO, Zynquista and our other drug candidates. These statements may include characterizations of the commercial performance of XERMELO, expected timing and outcome of regulatory review of applications for approval of Zynquista. The current status of the transition of responsibility from Sanofi for ongoing clinical studies and other activities related to Zynquista. The current status of our strategic alliance discussions with respect of Zynquista, extended timing and results of clinical trials of sotagliflozin, telotristat ethyl and our other drug candidates and a market opportunity for those programs.
This call may also contain forward-looking statement relating to Lexicon's growth and future operating results, discovery and development of other drugs candidates, strategic alliances and intellectual property, as well as other matters that are non-historical fact or information.
Various risks may cause Lexicon's actual results to differ materially from those expressed or implied in such forward looking statements. These risks include uncertainties related to the success of our commercialization efforts for XERMELO and regulatory review of applications for the approval of sotagliflozin, the timing and results of clinical trials and preclinical studies of sotagliflozin, telotristat ethyl and our other drug candidates, our dependence upon strategic alliances and other third-party relationship, our ability to obtain patent protection for our discoveries, limitations imposed by patents owned or controlled by third-parties and the requirements of substantial funding to conduct our research, development and commercialization activities.
For a list and description of the risks and uncertainties that we face, please see the reports we have filed with the Securities and Exchange Commission.
I would now like to turn